ATE488224T1 - Aerosol-formulierungen von diisobutyryl apomorphine - Google Patents

Aerosol-formulierungen von diisobutyryl apomorphine

Info

Publication number: ATE488224T1
Authority: AT; Austria
Prior art keywords: aerosol formulations; diisobutyryl; apomorphine; diisobutyryl apomorphine; aerosol
Prior art date: 2002-03-01

Application number

AT03743339T

Other languages

English (en)

Inventor

Rebecca Davies

David Ganderton

David Lewis

Brian Meakin

Gaetano Brambilla

Alessandra Ferraris

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-01

Filing date

2003-02-26

Publication date

2010-12-15

2003-02-26 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE488224T1 publication Critical patent/ATE488224T1/de

Links

VNUZLUGZUNVCTB-LJQANCHMSA-N [(6ar)-6-methyl-11-(2-methylpropanoyloxy)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10-yl] 2-methylpropanoate Chemical compound CN1CCC2=CC=CC3=C2[C@H]1CC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C13 VNUZLUGZUNVCTB-LJQANCHMSA-N 0.000 title 1
239000000443 aerosol Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT03743339T 2002-03-01 2003-02-26 Aerosol-formulierungen von diisobutyryl apomorphine ATE488224T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02004786A EP1340492A1 (de)	2002-03-01	2002-03-01	Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
PCT/EP2003/001962 WO2003074023A1 (en)	2002-03-01	2003-02-26	Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Publications (1)

Publication Number	Publication Date
ATE488224T1 true ATE488224T1 (de)	2010-12-15

Family

ID=27675679

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03743339T ATE488224T1 (de)	2002-03-01	2003-02-26	Aerosol-formulierungen von diisobutyryl apomorphine

Country Status (27)

Country	Link
US (1)	US20050129621A1 (de)
EP (2)	EP1340492A1 (de)
JP (1)	JP2005519094A (de)
KR (1)	KR20040091050A (de)
CN (2)	CN1638731A (de)
AR (2)	AR038643A1 (de)
AT (1)	ATE488224T1 (de)
AU (1)	AU2003215597B2 (de)
BR (1)	BR0303348A (de)
CA (1)	CA2477879C (de)
DE (1)	DE60334973D1 (de)
EA (1)	EA008571B1 (de)
ES (1)	ES2358293T3 (de)
GE (1)	GEP20063985B (de)
HR (1)	HRP20040751A2 (de)
IL (1)	IL163842A0 (de)
MA (1)	MA27107A1 (de)
MX (1)	MXPA04008370A (de)
NO (1)	NO20034874L (de)
NZ (1)	NZ535019A (de)
PE (1)	PE20030949A1 (de)
PL (1)	PL372261A1 (de)
TN (1)	TNSN04148A1 (de)
TW (1)	TW200304833A (de)
UA (2)	UA81238C2 (de)
WO (1)	WO2003074023A1 (de)
ZA (3)	ZA200406917B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
US6315985B1 (en) *	1999-06-18	2001-11-13	3M Innovative Properties Company	C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) *	2000-01-07	2003-07-15	Chiesi Farma Spa	Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) *	2000-05-22	2014-01-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
DE60103527T2 (de) *	2001-07-02	2005-06-16	Chiesi Farmaceutici S.P.A.	Optimierte Tobramycin-Formulierung zur Aerosolbildung
IL163843A0 (en) *	2002-03-01	2005-12-18	Chiesi Farma Spa	Formoterol superfine formulation
EP1415647A1 (de) *	2002-10-23	2004-05-06	CHIESI FARMACEUTICI S.p.A.	Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1452179A1 (de) *	2003-02-27	2004-09-01	CHIESI FARMACEUTICI S.p.A.	Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
GB0311701D0 (en) *	2003-05-21	2003-06-25	Karib Kemi Pharm Liited	Improved metered dose inhaler product
NZ545484A (en) *	2003-09-15	2009-09-25	Vectura Ltd	Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1595531A1 (de)	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stabile Arzneimittellösung für Druckdosierinhalatoren
IL177103A0 (en) *	2004-02-27	2006-12-10	Chiesi Farma Spa	Stable pharmaceutical solution formulations for pressurized metered dose inhalers
BRPI0512878A (pt) *	2004-07-02	2008-04-15	Boehringer Ingelheim Int	formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
RU2457832C2 (ru) *	2005-09-25	2012-08-10	Сипла Лимитед	Состав на основе тровентола
EP1968546A2 (de) *	2005-12-21	2008-09-17	Nitrox, LLC	Stabile s-nitrosothiol-formulierungen
DE102006017320A1 (de) *	2006-04-11	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (de) *	2007-07-03	2009-01-07	CHIESI FARMACEUTICI S.p.A.	Aktuator für einen Inhalator für abgemessene Dosen
UY31235A1 (es) *	2007-07-21	2009-03-02		Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
EP2211956A4 (de)	2007-10-10	2014-07-09	Parion Sciences Inc	Abgabe von osmolyten mit einer nasenkanüle
WO2010074753A1 (en)	2008-12-23	2010-07-01	Map Pharmaceuticals, Inc.	Inhalation devices and related methods for administration of sedative hypnotic compounds
US8598131B2 (en) *	2010-07-12	2013-12-03	Xellia Pharmaceuticals Aps	Method for treatment of lung infections by administration of aminoglycosides by aerolisation
CA2811692C (en)	2010-09-22	2020-02-18	The Board Of Regents Of The University Of Texas System	Novel block copolymer and micelle compositions and methods of use thereof
US8945605B2 (en) *	2011-06-07	2015-02-03	Parion Sciences, Inc.	Aerosol delivery systems, compositions and methods
US8778383B2 (en)	2011-06-07	2014-07-15	Parion Sciences, Inc.	Methods of treatment
CA2859209A1 (en) *	2011-12-20	2013-06-27	Map Pharmaceuticals, Inc.	Excipient-free aerosol formulation
GB201402513D0 (en) *	2014-02-13	2014-04-02	Cardiff Scintigraphics Ltd	Pressurised metered dose inhalers and method of manufacture
AU2015280412B2 (en)	2014-06-26	2018-07-26	Island Breeze Systems Ca, Llc	MDI related products and methods of use
WO2016187156A1 (en) *	2015-05-21	2016-11-24	Island Breeze Systems Ca, Llc	Propellant based metered dose inhaler and food applicators and applicators
US11129848B2 (en)	2017-08-08	2021-09-28	Perricone Hydrogen Water Company, Llc	Medication enhancement using hydrogen
GB201912686D0 (en) *	2019-09-04	2019-10-16	Reown Pharma Inc	Pharmaceutical composition
US11123365B2 (en)	2019-11-18	2021-09-21	Perricone Hydrogen Water Company, Llc	Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001505171A (ja) *	1996-12-04	2001-04-17	バイオグランアイルランド（アールアンドディ）リミテッド	製薬組成物及びその投与のための装置
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
GB2326334A (en) *	1997-06-13	1998-12-23	Chiesi Farma Spa	Pharmaceutical aerosol compositions
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) *	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
CA2317999C (en) *	1999-09-11	2004-11-09	Glaxo Group Limited	Pharmaceutical formulation of fluticasone propionate
IT1317720B1 (it) *	2000-01-07	2003-07-15	Chiesi Farma Spa	Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) *	2000-02-22	2003-07-15	Chiesi Farma Spa	Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
ES2280343T3 (es) *	2000-03-09	2007-09-16	Gw Pharma Limited	Composiciones farmaceuticas que contienen cannabis.
BR0005797A (pt) *	2000-03-20	2001-10-16	Abbott Lab	Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) *	2000-05-22	2014-01-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
IL163843A0 (en) *	2002-03-01	2005-12-18	Chiesi Farma Spa	Formoterol superfine formulation
EP1595531A1 (de) *	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stabile Arzneimittellösung für Druckdosierinhalatoren

2002
- 2002-03-01 EP EP02004786A patent/EP1340492A1/de not_active Withdrawn
2003
- 2003-02-26 JP JP2003572543A patent/JP2005519094A/ja active Pending
- 2003-02-26 GE GEAP8390A patent/GEP20063985B/en unknown
- 2003-02-26 NZ NZ535019A patent/NZ535019A/en unknown
- 2003-02-26 AT AT03743339T patent/ATE488224T1/de active
- 2003-02-26 MX MXPA04008370A patent/MXPA04008370A/es unknown
- 2003-02-26 EP EP03743339A patent/EP1480616B1/de not_active Expired - Lifetime
- 2003-02-26 PL PL03372261A patent/PL372261A1/xx not_active Application Discontinuation
- 2003-02-26 IL IL16384203A patent/IL163842A0/xx unknown
- 2003-02-26 BR BR0303348-1A patent/BR0303348A/pt not_active IP Right Cessation
- 2003-02-26 US US10/505,679 patent/US20050129621A1/en not_active Abandoned
- 2003-02-26 EA EA200401006A patent/EA008571B1/ru not_active IP Right Cessation
- 2003-02-26 ES ES03743339T patent/ES2358293T3/es not_active Expired - Lifetime
- 2003-02-26 DE DE60334973T patent/DE60334973D1/de not_active Expired - Lifetime
- 2003-02-26 AU AU2003215597A patent/AU2003215597B2/en not_active Ceased
- 2003-02-26 CA CA2477879A patent/CA2477879C/en not_active Expired - Fee Related
- 2003-02-26 CN CNA038049775A patent/CN1638731A/zh active Pending
- 2003-02-26 WO PCT/EP2003/001962 patent/WO2003074023A1/en not_active Ceased
- 2003-02-26 HR HRP20040751 patent/HRP20040751A2/hr not_active Application Discontinuation
- 2003-02-26 KR KR10-2004-7012649A patent/KR20040091050A/ko not_active Ceased
- 2003-02-26 UA UA20040806744A patent/UA81238C2/uk unknown
- 2003-02-27 UA UA20040806968A patent/UA80695C2/uk unknown
- 2003-02-27 TW TW092104190A patent/TW200304833A/zh unknown
- 2003-02-27 CN CNA2009100074339A patent/CN101502500A/zh active Pending
- 2003-02-28 PE PE2003000200A patent/PE20030949A1/es not_active Application Discontinuation
- 2003-02-28 AR ARP030100686A patent/AR038643A1/es unknown
- 2003-10-31 NO NO20034874A patent/NO20034874L/no not_active Application Discontinuation
2004
- 2004-08-06 TN TNP2004000148A patent/TNSN04148A1/en unknown
- 2004-08-09 MA MA27816A patent/MA27107A1/fr unknown
- 2004-08-31 ZA ZA200406917A patent/ZA200406917B/xx unknown
- 2004-08-31 ZA ZA200406918A patent/ZA200406918B/xx unknown
- 2004-08-31 ZA ZA200406919A patent/ZA200406919B/en unknown
2015
- 2015-08-19 AR ARP150102671A patent/AR101593A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0303348A (pt)	2004-07-13
US20050129621A1 (en)	2005-06-16
ZA200406919B (en)	2006-06-28
EA200401006A1 (ru)	2005-04-28
CA2477879A1 (en)	2003-09-12
CN101502500A (zh)	2009-08-12
TW200304833A (en)	2003-10-16
GEP20063985B (en)	2006-12-11
ES2358293T3 (es)	2011-05-09
KR20040091050A (ko)	2004-10-27
AR038643A1 (es)	2005-01-19
UA81238C2 (en)	2007-12-25
HRP20040751A2 (en)	2004-12-31
EP1480616A1 (de)	2004-12-01
CN1638731A (zh)	2005-07-13
NO20034874L (no)	2003-12-23
MA27107A1 (fr)	2004-12-20
AR101593A2 (es)	2016-12-28
ZA200406918B (en)	2006-06-28
DE60334973D1 (de)	2010-12-30
EA008571B1 (ru)	2007-06-29
NO20034874D0 (no)	2003-10-31
EP1340492A1 (de)	2003-09-03
NZ535019A (en)	2006-09-29
PL372261A1 (en)	2005-07-11
UA80695C2 (en)	2007-10-25
MXPA04008370A (es)	2004-11-26
WO2003074023A1 (en)	2003-09-12
CA2477879C (en)	2011-05-03
EP1480616B1 (de)	2010-11-17
PE20030949A1 (es)	2004-01-02
TNSN04148A1 (en)	2007-03-12
AU2003215597B2 (en)	2008-07-31
JP2005519094A (ja)	2005-06-30
AU2003215597A1 (en)	2003-09-16
ZA200406917B (en)	2006-06-28
IL163842A0 (en)	2005-12-18

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1480616

Country of ref document: EP

Publication	Publication Date	Title
DE60334973D1 (de)	2010-12-30	Aerosol-formulierungen von diisobutyryl apomorphine
EP1583997A4 (de)	2010-03-24	Photoresistentfernung
DE60332036D1 (de)	2010-05-20	Einteilige hand-airbrush
NO20044916L (no)	2004-12-16	Preparater av sulfinylacetamid
PT1513514E (pt)	2015-02-20	Formulações tópicas de hidroximatairesinol
IS7407A (is)	2004-08-17	Afleysing lausnarsambanda atorvastatínhálfkalsíums
ITMI20021038A0 (it)	2002-05-16	Disposizione di elettrodi
DE60327426D1 (de)	2009-06-10	Markierung von substraten
DE60323088D1 (de)	2008-10-02	Leberschützende wirkung der 10-o-p-hydroxybenzoylaucubin
FR2834647B1 (fr)	2004-12-31	Putter
UA6687S (uk)	2002-11-15	Комплект етикеток
UA6800S (uk)	2002-12-16	Комплект етикеток
UA6562S (uk)	2002-10-15	Комплект етикеток
UA6563S (uk)	2002-10-15	Комплект етикеток
UA6798S (uk)	2002-12-16	Комплект етикеток
UA6303S (uk)	2002-08-15	Комплект етикеток
UA7077S (uk)	2003-03-17	Комплект етикеток
UA6561S (uk)	2002-10-15	Комплект етикеток
UA7370S (uk)	2003-05-15	Комплект етикеток
UA6801S (uk)	2002-12-16	Комплект етикеток
UA6799S (uk)	2002-12-16	Комплект етикеток
UA6680S (uk)	2002-11-15	Комплект етикеток
UA6675S (uk)	2002-11-15	Комплект етикеток
SE0202115D0 (sv)	2002-07-08	Use of a composition
FI20020094A7 (fi)	2003-07-18	Nefriinintapaisten yhdisteiden käyttö